exemestane

She underwent neoadjuvant chemotherapy (doxorubicin/cyclophosphamide followed by paclitaxel), followed by a left radical mastectomy with axillary dissection. Hormonal therapy (goserelin and exemestane) and adjuvant radiotherapy were initiated...Hormone receptor status, tumor biology, and extent of disease all influence treatment decisions. This rare clinical scenario highlights the need for further research and specific management guidelines.

The patient developed a grade 3 eruptive, maculopapular dermatitis to exemestane and subsequently letrozole. Unusually, a third AI - anastrozole - has been well tolerated. Severe dAEs secondary to AIs are rare, and there is a lack of evidence-based research to guide management of these reactions.

P=N/A, N=1, Active, not recruiting, Pfizer | Recruiting --> Active, not recruiting | N=5087 --> 1

Everolimus is an mammalian target of rapamycin (mTOR) inhibitor used in combination with exemestane for metastatic ER+BC. Combining trametinib with everolimus treatment significantly reduces resistant cell growth. Our results demonstrate that everolimus-resistant ER+BC cells evade therapy via alternate growth-factor signaling linked to activation of SMARCD3 regulons, which can be therapeutically targeted using MEK1/2 inhibitors.

P3, N=1017, Completed, UNICANCER | Active, not recruiting --> Completed

Ten molecules were found to inhibit aromatase with IC50 values ranging between 0.04 and 2.31 µM, more potent than the clinical drug, exemestane (IC50 = 2.40 µM)...Molecular docking and dynamics simulations predicted that hydrophobic interactions are most important for aromatase inhibition, whereas chelation activities can also contribute to inhibition. The series have drug-like profiles with acceptable toxicity, and are pharmacokinetically compatible for oral drug administration.

P3, N=920, Recruiting, Eli Lilly and Company | Not yet recruiting --> Recruiting

In this study of premenopausal women with hormone receptor-positive breast cancer, BCI (H/I) status did not clearly predict greater benefit of adjuvant exemestane plus OFS vs tamoxifen plus OFS for women with BCI (H/I)-low tumors than for those with BCI (H/I)-high tumors; BCI continuous indices were reconfirmed as prognostic for premenopausal women. These findings support prior results of SOFT, which compared tamoxifen-alone vs OFS with either exemestane or tamoxifen, indicating premenopausal patients with BCI (H/I)-low tumors may benefit from more intensive endocrine therapy.

P=N/A, N=30, Not yet recruiting, Harbin Medical University Affiliated Cancer Hospital; Harbin Medical University Affiliated Cancer Hospital

The patient achieved a remarkably prolonged progression-free survival (PFS) of 37 months on this combination therapy, representing the longest period of disease control in her metastatic course. Although eventual progression occurred (new axillary lymph node metastasis and suspected hepatic recurrence), this case demonstrates the exceptional efficacy and durable disease control achievable with Fluzoparib plus Exemestane in a pretreated patient with gBRCA2-mutated HR+/HER2-advanced breast cancer, highlighting a promising therapeutic approach for this molecularly defined population.

P=N/A, N=5087, Recruiting, Pfizer | Active, not recruiting --> Recruiting

These collective results indicate that exemestane induces hepatotoxicity in zebrafish primarily through activation of the p53 signaling pathway. This study provides valuable insights into the potential hepatotoxic effects of exemestane, offering important references for its clinical safety evaluation.